The 6th annual Roll on Capitol Hill, organized by the United Spinal Association, will advocate for greater access to properly configured and medically-necessary wheelchairs for people with spinal cord injuries and disorders (SCI/D). The event will take place from June 11-14 in Washington, D.C. Andrea Dalzell, Ms. Wheelchair New…
News
Researchers have developed an antibody, called armanezumab, which specifically targets defective tau protein. The molecule has potential for the treatment of amyotrophic lateral sclerosis (ALS), among other diseases. According to results of the study “Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency,”…
The first treatment for amyotrophic lateral sclerosis (ALS) in more than two decades, Radicava (edaravone), has been approved by the U.S. Food and Drug Administration and will soon be available to patients. The May 5 FDA decision, hailed by physicians and ALS advocates, brings hope to the ALS community that treatment development, after a…
ALS Ride for Life is launching its 20th annual ride and celebrating the anniversary with another event to raise awareness and funds to accelerate the discovery of a cure for amyotrophic lateral sclerosis (ALS). Chris Pendergast founded Ride for Life in 1997 after being diagnosed with ALS in…
Defects in RNA processing and transport, as well as protein folding, may contribute to amyotrophic lateral sclerosis (ALS) pathology, according to the results of recent research. The study, “Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis,” was published in the journal PLOS…
Pfizer and AbbVie are pumping $10 million into Aquinnah Pharmaceuticals‘ effort to develop a revolutionary approach to treating neurodegenerative diseases — one that could arrest, or even reverse, the progression of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and other conditions. Takeda Pharmaceuticals invested $5 million in Aquinnah’s program in December 2015.
May is ALS Awareness Month and the ALS community is seeking the help of individuals willing to participate, advocate and donate to advance the fight toward a world free of amyotrophic lateral sclerosis, commonly known as “Lou Gehrig’s Disease.” The ALS Association is a national non-profit organization dedicated to building…
Biohaven Pharmaceuticals is pushing hard for regulatory approval and development of its two investigational drugs for amyotrophic lateral sclerosis (ALS): BHV-0223, a sublingual form of Rilutek (riluzole), and BHV-4157, a compound that modulates the neurotransmitter glutamate. After more than 20 years, Rilutek remains the only approved treatment for people with…
More amyotrophic lateral sclerosis (ALS) patients survived among those who completed a Phase 2 trial of MediciNova’s Ibudilast (MN-166), compared to those who dropped out of the study, according to an exploratory interim analysis. But the data, presented at the American Academy of Neurology (AAN) 2017 Annual Meeting…
The amyotrophic lateral sclerosis (ALS) investigational drug edaravone will be the focus of four presentations by MT Pharma America in Boston. The presentations, which include data on edaravone and an analysis evaluating clinically relevant symptoms of ALS, are taking place at the 69th Annual Meeting of the American…
Recent Posts
- Mourning the loss of a leader, friend, and advocate for women with ALS
- Developer to test ALS therapy with help of Mass General’s MyMatch
- A story of a family’s loss offers guidance amid my grief with ALS
- MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS
- Holding the line: Why I’d keep my ALS progression exactly as it is